PCR Technologies Market Forecast, Trends, and Global Size by 2030

The PCR technologies market size is projected to surge from US$ 13,101.87 million in 2022 to US$ 24,524.50 million by 2030; the market is estimated to grow at a CAGR of 8.2% during 2022–2030.

Analyst Perspective:

A popular molecular biology technique called polymerase chain reaction (PCR) amplifies DNA and RNA sequences, enabling various applications in research, diagnostics, and other areas. Both traditional PCR techniques and state-of-the-art versions, such as real-time PCR (qPCR) and digital PCR (dPCR), are available on the market. The market for PCR technologies is highly competitive, with a few large manufacturers controlling the sector. These companies continually spend money on research and development to bring new products to market and improve their current offerings. Sales of PCR machines have increased dramatically due to increased demand for testing, and also rapid and multiplex PCR tests have been specifically tailored for COVID-19.

Technological advancements have improved performance, sensitivity, and ease of use in PCR instruments, reagents, and software. Workflows have been streamlined through automation and integration, enabling high throughput testing and speeding turnaround. The increasing need for molecular diagnostics, genetic testing, and personalized therapy is one of the main causes of the market growth. Further, with the increasing prevalence of chronic diseases, developments in genomic research, and the demand for early detection of diseases, the development of technology significantly influences market growth.

Market Overview:

PCR is crucial in clinical settings as it enables rapid and precise detection of genetic variants, infectious diseases, and biomarkers. In addition, the need for PCR-based diagnostics has been fueled due to the increasing prevalence of chronic diseases and developments in genomic research. Additionally, automation, integration, and ongoing improvements in PCR instruments, chemicals, and software have increased the performance, sensitivity, and efficiency of workflows, thereby driving the expansion of the market.

The COVID-19 pandemic further increased the demand for PCR technology, particularly COVID-19 testing. The adoption of PCR technology has been primarily driven by increasing demand for molecular diagnostics, genetic testing, and personalized medicine. A key barrier is the high cost of PCR equipment and supplies, making them less accessible in resource-limited settings. PCR technology is made possible by the growing interest in precision medicine and the need for companion diagnostics. In addition, combining PCR with other technologies, such as microfluidics and next-generation sequencing (NGS), opens up new research opportunities and improves diagnostic capabilities. Furthermore, developing innovative PCR assays for emerging infectious diseases and increasing applications in forensics, agriculture, and environmental monitoring offer great market expansion and diversification prospects.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

PCR Technology Market: Strategic Insights

Market Size Value in	US$ 13,101.87 million in 2022
Market Size Value by	US$ 24,524.50 million by 2030
Growth rate	CAGR of 8.2% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Market Driver and Restraint:

According to the National Organization's information on genetic conditions or congenital disabilities, genetic disorders are rare conditions, but they collectively comprise over 15,500 positive diagnoses every year. Estimates published in a report by MJH Life Sciences (US) in 2022 state that ~300,000 newborns are born with sickle cell disease (SCD) globally every year, accounting for ∼5% of the global population. In the US, SCD is one of the most prevalent genetic conditions. According to the Centers for Disease Control and Prevention (CDC), 1 in 500 African Americans is affected by an SCD, and ∼1 in 12 of them suffer from the autosomal recessive mutation. As per the June 2020 report by Novartis AG (Switzerland), ∼15,000 individuals and 270 newborns are diagnosed with SCDs every year. The disease is most prevalent in emerging nations such as India. Among India's tribal communities, ∼18 million people exhibit sickle cell traits (SCTs), and 1.4 million people are suffering from SCDs. As a result of the rising incidence of SCDs, the adoption of digital polymerase chain reaction (dPCR) is increasing in pathology centers, wherein this technology is being exploited for targeting various DNA-specific sequences to confirm diagnoses and design various clinical tests. dPCR can target specific DNA sequences in just one molecule of DNA. This tool allows researchers to detect rare genetic mutations that are difficult to identify using real-time PCR. Government and federal agencies worldwide recognize the role of quantitative polymerase chain reaction (qPCR) and dPCR products in genome-based research. In 2021, Camena Bioscience, a synthetic biology startup that supplies genes to the biotechnology and pharmaceutical sectors, completed a US$ 10 million Series A funding round headed by Mercia. With the additional funds, the company expanded its operations and continued the development of its ground-breaking DNA synthesis platform—gSynth. Therefore, the increasing availability of financial support for research and development in disease-specific genomics and the rising prevalence of genetic and infectious diseases propels the demand for PCR technologies.

According to SafePath Laboratories, LLC, the minimum cost of an entry-level PCR machine is ~US$ 10,000. Since dPCR is a modern PCR technology, most manufacturers often set a premium price of nearly US$ 120,000 for their state-of-the-art dPCR instruments; however, qPCR machines cost ~US$ 90,000. The price of manual dPCR ranges from US$ 65,000 to US$ 70,000, and it can rise to US$ 100,000 for automated dPCRs. In the US, as of July 2022, the average price of a dPCR instrument was estimated to be US$ 55,000–120,000, based on the instrument design and intended use/application. The cost of a real-time PCR machine ranges from US$ 20,000 to US$ 30,000. In addition, consumables, reagents, and accessories required for performing PCR tests are expensive. Such high prices limit the demand for PCR instruments and reagents among end users who prefer cheaper genomic techniques, particularly institutional researchers, small CROs, and pharmaceutical and biotechnology companies. RT-PCR tests are widely preferred to diagnose respiratory infectious diseases. In September 2020, F. Hoffmann-La Roche AG launched the SARS-CoV-2 Rapid Antigen Test in Europe. The test kit produces results in 15 minutes. Similarly, in March 2021, XPhyto Therapeutics Corp. received approval in Europe for its rapid COVID-19 test system that provides results in just 25 minutes, much quicker than rapid PCR testing. Therefore, the high costs of PCR technology and the availability of alternative options limit the growth of the PCR technologies market

Segmental Analysis:

The PCR, based on technology, is divided into real-time PCR, conventional PCR, reverse transcription, digital PCR (dPCR), multiplex RT-PCR, hot start PCR, and others. The real-time PCR segment held the largest market share in 2022, and the same is predicted to register the highest CAGR of 8.8% during 2022–2030. Real-time PCR is a nuclear-based approach for identifying specific genetic material in any disease, including viruses. Real-time PCR has become one of the most extensively used methods of gene quantification. Because of its dynamic range, remarkable sensitivity, ability to be very sequence-specific, no post-amplification processing, and ability to increase sample throughput.

Based on the offering, the PCR is segmented into reagents and consumables, instruments, and software and services. The reagents and consumables segment held the largest market share in 2022, and the same is said to register the highest CAGR during 2022–2030.

Based on application, the PCR technologies market is segmented into gene expression analysis, genetic sequencing, genotyping, nucleic acid synthesis, standard validation, point of care diagnostic application, environmental application, and others. The gene expression analysis segment held a larger market share in 2022. Moreover, the same segment is anticipated to grow a higher CAGR during 2022–2030.

Based on end user, the PCR technologies market is divided into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, and others. The hospitals and diagnostic centers segment held the largest market share in 2022. Moreover, the same segment is projected to register the highest CAGR during 2022–2030.

Access Data

Regional Analysis:

North America is the dominating region in the PCR. The North America PCR was valued at US$ 5,075.81 million in 2022 and is projected to reach US$ 9,634.86 million by 2030; it is expected to register a CAGR of 8.30% during 2022–2030. The North America PCR is segmented into the US, Canada, and Mexico. The increased demand for innovative products from bioanalytical instrument manufacturers and PCR companies, the presence of key market players, and extensive R&D conducted across various academic and research institutes are factors leading to market growth in the region. The US is seeking significant funding from public and private organizations to encourage investments in advanced research methodologies. For instance, the International Centre for Genetic Engineering and Biotechnology aims to stimulate collaborative research in the member states. The US Food and Drug Administration (USFDA) is committed to ensuring the safety of biotechnology products. The US actively participates in various research groups and organizations to conduct scientific conferences, workshops, and events that help exchange the trends and latest research studies based on PCR within different geographies.

Europe holds the second-largest share of the PCR technologies market. Market growth in this region is mainly accredited to the funds made available by government and private organizations for advanced research, the launch of innovative technologies for artificial DNA synthesis, and an increase in various research studies for novel technology-based applications.

The Asia Pacific PCR technologies market holds the highest CAGR. The factors contributing to the market progress in this region include the increasing foreign direct investments, the large availability of highly skilled, efficient workforces, and the streamlining of government policies, resulting in high investments in the biotechnology sector. In addition, increasing cases of infectious and chronic diseases and government and non-government initiatives fuel the growth of the PCR technologies market in Asia Pacific.

Key Player Analysis:

Atila Biosystems, Thermo Fisher Scientific, Inc.; Takara Bio Inc.; Standard BioTools Inc.; F.Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc;  Agilent Technologies, BIOMERIEUX, QIAGEN, Promega Corporation; Becton, Dickinson, and Company; Visby Medical, Inc.; and Ellume Limited are the key PCR technologies players analyzed during the market study. Due to their diversified product portfolio, F. Hoffman-La Roche AG and Thermo Fisher Scientific, Inc. are the top two PCR technologies market players.

Recent Developments: 

Companies in the PCR technologies market highly adopt inorganic and organic strategies such as mergers and acquisitions. A few recent key market developments are listed below:

• In March 2023, Stilla Technologies and Atila Biosystems announced that they would collaborate to create digital PCR kits for liquid biopsy applications related to cancer. The companies will work together to commercialize Atila's digital PCR kits and assays that can be used with Stilla's six-color Naica system. The kits, intended solely for research purposes, are designed to identify circulating tumor DNA from liquid biopsy samples obtained from individuals suffering from malignancies such as breast, lung, melanoma, prostate, colorectal, and others.
• In July 2023, QIAGEN announced the expansion of its digital PCR (dPCR) offering to develop cell and gene therapies in the biopharma industry. The company partnered with Niba Labs to offer biopharma customers customized digital PCR assay design services. Also, it launched the new CGT Viral Vector Lysis Kit that enables a standardized workflow from cell lysates to absolute and precise quantification of viral titers for multiple serotypes.
• In October 2023, QIAGEN and Myriad Genetics announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the US clinical market and providing distributable companion diagnostic test kits for the global market.
• In November 2023, Qiagen launched new kits for use on its QIAcuity systems and a major new software update designed to expand the portfolio of applications for the use of digital PCR technology in areas such as cell and gene therapies, DNA and RNA quantification, as well as food and pharmaceuticals safety.